PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.7 pts more than its Other Financial Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biogen Pharmachem Industries (formerly Sun Techno Overseas) reported un-audited results for Q3 FY26 (quarter ended Dec 31, 2025) and 9M FY26, approved at its board meeting on February 11, 2026. The company reported total operating income of Rs. 54.19 lacs in Q3 FY26, up sharply from Rs. 22.76 lacs in Q3 FY25. For the nine-month period, operating income swung to Rs. 197.98 lacs from a negative Rs. (51.39) lacs a year earlier. Profit after tax for Q3 FY26 stood at Rs. 46.23 lacs versus a loss of Rs. (31.49) lacs in Q3 FY25, while 9M FY26 PAT was Rs. 131.56 lacs versus a loss of Rs. (147.05) lacs in 9M FY25. Notably, Revenue from Operations is nil across all periods, with income classified entirely as 'Other Operating Income'. Other Equity remains negative at Rs. (903.26) lacs. The statutory auditor, Goenka Mehta & Associates, issued a clean limited review report with no qualifications.
The sharp swing from losses to profitability is a positive signal for shareholders, though it should be viewed with caution since the company has no core revenue from operations and is generating gains from other operating income, while accumulated losses have wiped out its reserves. The stock may see short-term relief, but sustainability of these earnings remains questionable without any underlying operating business.